Case Report of Kikuchi-Fujimoto Disease from Sub-Saharan Africa: An Important Mimic of Tuberculous Lymphadenitis by Sharma, Karishma et al.
eCommons@AKU 
Internal Medicine, East Africa Medical College, East Africa 
1-2020 
Case Report of Kikuchi-Fujimoto Disease from Sub-Saharan 
Africa: An Important Mimic of Tuberculous Lymphadenitis 
Karishma Sharma 
Aga Khan University, karishma.sharma@aku.edu 
Fredrick Otieno 
Aga Khan University, fredrick.otieno@aku.edu 
Reena Shah 
Aga Khan University, reena.shah@aku.edu 
Follow this and additional works at: https://ecommons.aku.edu/eastafrica_fhs_mc_intern_med 
 Part of the Internal Medicine Commons 
Recommended Citation 
Sharma, K., Otieno, F., Shah, R. (2020). Case Report of Kikuchi-Fujimoto Disease from Sub-Saharan Africa: 
An Important Mimic of Tuberculous Lymphadenitis. Case Reports in Medicine, 2020, 1-6. 
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_intern_med/206 
Case Report
Case Report of Kikuchi-Fujimoto Disease from Sub-Saharan
Africa: An Important Mimic of Tuberculous Lymphadenitis
Karishma Sharma , Fredrick Otieno, and Reena Shah
Department of Medicine, Aga Khan University Hospital, Nairobi, Kenya
Correspondence should be addressed to Reena Shah; reena.shah@aku.edu
Received 27 May 2019; Revised 8 October 2019; Accepted 19 December 2019; Published 6 January 2020
Academic Editor: Jagdish Butany
Copyright © 2020 Karishma Sharma et al. +is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Kikuchi-Fujimoto disease (KFD) is a rare form of painful lymphadenopathy, usually cervical, which is more common in Southeast
Asia and rarely reported from Africa. Symptoms are usually nonspecific (fever, night sweats, etc.), and can mimic more common
diseases such as tuberculosis (TB) in endemic areas. We report a case of a 29-year-old black African woman who was admitted
with headache, neck pain, fever, and lymphadenopathy. She was found to have aseptic meningitis, eventually attributed to TB
based on cervical node biopsy, although further histology suggested KFD. Blood tests for systemic lupus erythematosus (SLE) were
negative; she had already been commenced on anti-TB treatment and had responded well and so was continued with this therapy.
She was also later diagnosed with Hashimoto’s thyroiditis 3 months after her diagnosis of KFD. Five months after stopping TB
treatment, she was readmitted with the same symptoms and associated painless lymphadenopathy. Repeat biopsy was mor-
phologically similar to that of 2017, and repeat evaluation confirmed SLE. She has since been managed by a rheumatologist and
continues to do well.
1. Introduction
Kikuchi-Fujimoto disease (KFD) is a rare form of painful
lymphadenopathy which is more common in Southeast
Asia. KFD is not very well described in Africa, with very few
reports described in the literature. +e lymphadenopathy is
usually cervical with associated nonspecific symptoms of
fever and night sweats, which makes the diagnosis more
challenging as the differential diagnosis is wide. We describe
a young female, who presented with aseptic meningitis
initially thought to be due to tuberculous meningitis and
later confirmed to have KFD on lymph node biopsy, and
subsequently diagnosed with Hashimoto’s thyroiditis and
systemic lupus erythematosus (SLE) 3 and 18 months after
initial presentation.
2. Case Presentation
A 29-year-old black African woman presented to the
emergency department with headache and fever for 5 days.
Brain imaging was normal, and lumbar puncture for cere-
brospinal fluid (CSF) analysis showed a raised white cell
count (WBC) of 31/mm3 with 95% lymphocytosis, elevated
CSF protein, and borderline high CSF adenine deaminase
levels of 18.1U/L. CSF Ziehl–Neelsen stain, GeneXpert, and
culture for Mycobacterium tuberculosis (TB) were negative.
Blood tests are in accordance with Table 1. Her headache and
fever resolved with oral paracetamol, and she was discharged
with a diagnosis of aseptic meningitis.
However, she was readmitted with worsening neck pain
and headache 2weeks later and was found to have signifi-
cantly enlarged cervical lymph nodes. Further evaluation
with an MRI scan of the neck showed features in keeping
with TB lymphadenitis. A repeat of laboratory workup (refer
to Table 1) remained negative. She also had a positive EBV
IgG but with a negative serum IgM. A cervical lymph node
was biopsied. Histopathological examination revealed nec-
rotizing lymphadenitis with no granulomas (Figures 1(a)
and 1(b)). Since the histologic appearance was in-
distinguishable from that of TB lymphadenitis, the patient
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Table 1: Laboratory results summarized from 2017 to 2019.
Variable Reference range Aug 2017 Sept 2017 Jan2018
July
2018 Feb 2019
White blood cell 4–10 (∗109/L) 2.51 3.19 2.06
Neutrophil count 2–7 (∗109/L) 1.16 2.12 1.14
Lymphocyte count 1–3 (∗109/L) 1.10 0.81 0.80
Hemoglobin 11.5–16.5 (g/dl) 10.2 11 11
Platelet count 150–450 (∗109/L) 118 153 85
ESR (Erythrocyte
sedimentation rate) 0–20 (mm/hr) 44 61
CRP (C-reactive protein) 0–5 (mg/l) 1.63 15.1
AST (aspartate transaminase) 0–35 (U/L) 22 23.5 33.4
ALT (alanine transaminase) 0–35 (U/L) 17.7 13.9 15.6
Creatinine 58–98(micromol/l) 65 59 60
HIV Elisa Neg Neg Neg
CSF:
Cell count 0–5 (mm3) 31.25 295 <5
Neut % 6 4
Lymph % 94 96
Glucose 2.22–3.89(mmol/l) 2.39 3.51 2.69
Protein 0.15–0.45 (g/l) 0.52 0.56 0.44
Tb Gene expert Neg Neg
CSF adenine deaminase 0–5 (U/L) 18.41 0.29
CSF culture No growth No growth No growth
CSF viral PCR-
herpes + enterovirus Neg Neg






(v) West Nile virus
(vi) Chikungunya
Neg Neg
Malaria parasite Absent Absent
Blood culture No growth No growth
Urine culture No growth No growth
ANA (antinuclear antibody) Neg Positive 1 : 320speckled




Direct Coombs test Neg
Ferritin 13–150 (ng/ml) Normal
Lipid profile Normal
TSH (thyroid stimulating
hormone) 0.27–4.2 (pg/ml) 1.68 49.77 25.24 4.23
T3 2–4.4 (pg/ml) 2.88 1.67 2.97 1.87
T4 0.97–1.58 (ng/ml) 0.87 0.32 0.84 0.86
Anti-TPO antibodies <34 (IU/ml) 290
Antithyroglobulin <115 (IU/ml) 226
TSH receptor antibodies <1.22 0.468
Lymph node biopsy Refer to Figures 1(a) and1(b) Refer to Figure 1(c)
Tissue Tb culture Neg
Bone marrow aspirate Normocellular
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was commenced on TB treatment (ATT) and was reviewed
in a clinic 3 weeks later and found to have improved
significantly.
+e slides were sent for a second opinion overseas
(USA), where the cervical biopsy was noted to show marked
architectural effacement with large areas of necrosis con-
taining abundant apoptotic debris. +e adjacent viable areas
contained numerous histiocytes, small lymphocytes, occa-
sional plasma cells, and immunoblasts (Figures 1(a) and
1(b)). Hematoxylin bodies were not identified. Immuno-
histochemistry performed on the slides was CD20/PAX5 (B-
cell marker)-positive, CD68 (histiocyte marker)-positive,
and CD123 (plasmacytoid dendritic cells)-positive with a Ki
of 67–60%.
+ese findings were in keeping with a diagnosis of
histiocytic necrotizing lymphadenitis likely secondary to
either KFD or SLE. However, given the patient was
responding well to the TB therapy and she had screened
negatively for SLE, she was continued on the treatment.
+ree months into her TB treatment, she was found to have
an elevated thyroid stimulating hormone (TSH) of 47 pg/ml
with low thyroxine and thyronine levels and positive anti-
thyroid peroxidase and thyroglobulin antibodies in keeping
with Hashimoto’s thyroiditis. +e patient completed 12
months of TB treatment and remained well and was
discharged.
However, 5 months later, she presented to the infectious
disease’s clinic with a 1-month relapse of the same symp-
toms. She reported a history of travel to a malaria-endemic
region 2 weeks prior and had taken a complete course of self-
prescribed antimalarial medication with no resolution of
symptoms. On examination, she had a temperature of 38°C
but otherwise normal vital signs and large >1 cm bilateral
nontender nonmatted upper cervical lymphadenopathy, but
otherwise a normal physical examination with no
meningism.
Investigations on this occasion are summarized in
Table 1.
Interestingly, the repeat autoimmune screen revealed
ANA positive with titers of 1 : 320 and a speckled pattern.
Her ENA anti-SS-A/RO-52 was also positive. +e remainder
(a) (b)
(c)
Figure 1: (a) Lymph node biopsy 2017 (low-power view): partial effacement of architecture with large area of necrosis with no acute
inflammatory cell infiltrate in keeping with Kikuchi’s disease. (b) Lymph node biopsy 2017 (high-power view): numerous apoptotic bodies
with histiocytes. (c) Lymph node biopsy 2019: numerous foci of necrosis with apoptotic bodies with scattered histiocytes. Absence of acute
inflammatory infiltrate and hematoxylin bodies in keeping with Kikuchi’s disease.
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of her evaluation was unremarkable except for persistent
leucopenia, anemia, and thrombocytopenia.
She was reviewed by the rheumatologist and diagnosed
as a case of systemic lupus erythematosus after she met 4
components of the SLICC criteria which included throm-
bocytopenia, leucopenia, arthritis, and positive ANA. Her
Anti-Ro antibody was also positive and even though not part
of the SLICC criteria is still in keeping with the diagnosis of
SLE. While in hospital, her fevers settled spontaneously with
antipyretics. At the time of discharge, she was initiated on
prednisolone, azathioprine, and hydroxychloroquine which
she is currently on and is asymptomatic. She currently re-
mains on follow-up in the Rheumatology clinic.
3. Discussion
Kikuchi-Fujimoto disease, also known as histiocytic nec-
rotizing lymphadenitis, was first described in 1972 [1]. It is a
rare self-limiting lymphadenopathy, more commonly de-
scribed in females, those aged 20–40 years and are of
Southeast Asia origin [2, 3]. Although less common within
the African population, a few cases of the disease have been
reported from Gabon, Senegal, Morocco, and Tunisia [4–6].
+e disease affects both adults and children. +e sex ratio is
variable in the pediatric age group with males affected more
than females, which is reversed in adults [7].
+e exact pathophysiology of KFD is not known, but the
two theories postulated are infectious and autoimmune
etiology [8]. Xu et al. identified CMV,EBV, HHV-6, HHV-7,
Parvovirus B19, and mycobacterial species from lymph node
samples of 153 patients in China with KFD [9]. KFD has
been described in association with SLE, Still’s disease,
Wegener’s granulomatosis, Graves’ disease, and Sjogren’s
disease [3]. Tanaka et al. found higher frequencies of the
HLA DPA1∗ 01 and DPB1∗ 0202 allele in Japanese patients
with KFD [10]. Familial cases of KFD have been reported in
the literature [11].
+e largest published series of 244 KFD cases has shown
that fever (35%), fatigue (7%), and joint pain (7%) are the
most frequent symptoms, and lymphadenopathy (100%),
leucopenia (43%), high erythrocyte sedimentation rate
(40%), anemia (23%), and erythematous rashes (10%) are the
most common findings [12]. Our patient had high fever,
lymphadenopathy, leukopenia, anemia, and high ESR.
Cervical lymphadenopathy is the commonest site for
lymphadenopathy and is usually painful [13].
+e clinical picture of KFD is often nonspecific and can
be in keeping with several diagnoses such as infectious
mononucleosis, bacterial lymphadenitis (mainly tubercu-
losis which is highly endemic in Africa), malignant lym-
phoma, or metastatic cancer [12]. +e nonspecific nature of
presentation is associated with diagnostic delay and mis-
diagnosis of patients [14, 15], especially in TB endemic
regions such as Kenya, where patients get unnecessary ATT
treatment.
Baenas et al. noted three patterns of presentation of
association between KFD and SLE which are before the onset
of SLE (30%), simultaneous occurrence of both disorders
(47%), and KFD after SLE (23%) [16]. Goldblatt et al.
reported 4 cases of patients who developed SLE after 4–13
months of diagnosis with KFD [17]. Since SLE evolves over
many years and patients may not meet the diagnostic criteria
at onset or in the initial phases of the disease, it is likely that
the initial diagnosis of KFD in this patient may have been an
attenuated form of SLE [18]. However, it remains difficult to
reach this conclusion since the diagnosis is dependent on
standard diagnostic criteria which our patient did not meet
until much later in the disease. Interestingly, she has not had
any flares of her disease following the initiation of her
treatment for SLE, and it remains unclear whether her initial
response to the anti-TB medication was more due to the
steroids used in the treatment of CNS tuberculosis. Due to
the association of KFD with SLE, follow-up and screening of
patients with KFD for later diagnosis of SLE are recom-
mended [19].
CNS manifestations of KFD are rare, and so far, aseptic
meningitis, encephalitis, and cerebellar ataxia have been
reported in the literature [20, 21]. Aseptic meningitis is the
commonest neurological presentation of Kikuchi’s disease
[22]. +e CSF white cell count may range from 60 to
170mm3 and may present as recurrent meningitis within
intervals of 1 month–11 years [23]. +e diagnosis of KFD as
a cause of the aseptic meningitis is made following exclusion
of other potential reversible causes.
Hashimoto’s thyroiditis has also been associated with
Kikuchi disease. In majority of the cases, KFD and Hashi-
moto’s thyroiditis occurred concurrently; however, in three
cases, the diagnosis of Hashimoto’s thyroiditis preceded that
of KFD [24]. Previous reported cases note that it is more
common in females and may be positive for ANA, com-
plement, and antiphospholipid antibodies. Most reported
cases complete resolution within a year following supportive
care in some patients and steroids in others [24]. We came
across a case report of a 17-year-old female with concurrent
SLE and Hashimoto’s thyroiditis who responded well to
steroids and hydroxychloroquine. [25] Similarly, Aqel et al.
reported a case of KFD in Saudi Arabia with Hashimoto’s
thyroiditis and mixed connective tissue disease [26].
+e diagnosis of Kikuchi-Fujimoto disease is made on
biopsy. Histologically, lymph nodes usually have partially
preserved architecture with follicular hyperplasia. Necrotic
foci show abundant karyorrhectic nuclear debris and a large
accumulation of histiocytes at the edge of necrosis. +e
histiocytes in KFD are positive for lysozyme, myeloperox-
idase, CD68, CD163, and CD4. +e lymphocytes in the
lesions are mostly CD3-positive T cells demonstrating a
predominance of CD8 compared with CD4, with very few
CD20-positive B cells [3]. In contrast, lymphadenitis from
TB classically has the presence of well/poorly defined
granulomas with areas of caseous necrosis [27]. +e pro-
liferative stage of KFD may be confused with lymphoma due
to presence of large atypical cells and immunoblasts of T-cell
lineage origin [18].
+ere is no consensus regarding treatment for this
disease. Patients with mild disease respond to supportive
care with antipyretics and NSAIDs. In contrast, those with
extranodal disease with CNS and lung involvement may
respond to short courses of corticosteroids [28].
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During the first admission, the patient was on dexa-
methasone as part of her TB meningitis treatment. +is
could explain the initial resolution of her symptoms. Irre-
spective of the form of intervention, the prognosis of the
condition is reported as favorable. However, there have been
reported cases of death especially in patients who develop
DIC [29].
Song et al. reported a higher incidence rate of relapse in
ANA-positive cases and identified fever, fatigue, extranodal
involvement, and positive fluorescence antinuclear antibody
as predictive factors for relapse [30].
To the best of our knowledge, very few cases of this
disorder have been reported so far from Africa. +e chal-
lenges with making this diagnosis we believe are multiple
including lack of clinician familiarity with disorder, few case
reports, nonspecific signs and symptoms, poor laboratory
support, and presence of alternative diagnosis especially
tuberculosis in our set up.
Consent
Written informed consent for publication of the clinical
details and clinical images was obtained from the patient.
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